Analysts Offer Predictions for INKT FY2029 Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – HC Wainwright issued their FY2029 EPS estimates for shares of MiNK Therapeutics in a note issued to investors on Tuesday, February 25th. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.02) per share for the year. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share.

Separately, Robert W. Baird decreased their target price on MiNK Therapeutics from $80.00 to $40.00 and set an “outperform” rating on the stock in a report on Friday, November 15th.

MiNK Therapeutics Stock Down 8.6 %

Shares of NASDAQ INKT opened at $9.73 on Wednesday. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $19.00. The company has a market cap of $38.56 million, a PE ratio of -2.49 and a beta of 0.17. The business’s 50 day moving average price is $8.29 and its two-hundred day moving average price is $7.71.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.